IL5 and eosinophilic granulomatosis with polyangiitis: In the recent study evaluating mepolizumab in EGPA (see Clinical Trials Evaluating Antibodies That Target IL-5 or Its Receptor in Systemic HESs), 94% of enrolled subjects had sinonasal abnormalities (64).